Science Publications

Sign Up
Sign In
Submit
Current Research in Public Health
Cite This Article Share Download PDF XML
  1. Home
  2. Journals
  3. Current Research in Public Health
  4. Archive
  5. Volume 3, Issue 1, 2023
  6. Article
Case Series Open Access September 01, 2023

Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia

Masafumi Seki 1, 2,*, Seigi Lee 2, Kokyo Sakurada 3, Yutaka Miyawaki 2, Ayumu Masuoka 4 and Futoshi Kotajima 4
1
Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan
2
Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan
3
Division of Neurological Surgery, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan
4
Respiratory Support Team, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan
Publihed in: Current Research in Public Health (Volume 3, Issue 1, 2023)
Page(s): 5-11
DOI: 10.31586/gjmcr.2023.754
Received
July 04, 2023
Revised
August 20, 2023
Accepted
August 31, 2023
Published
September 01, 2023
Keywords
Blood Stream Infection; Ceftolozane/Tazobactam (CTLZ/TAZ); Piperacillin/Tazobactam (PIPC/TAZ); Pseudomonas aeruginosa
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright: Copyright © The Author(s), 2023. Published by Scientific Publications
Article metrics
Views
1955
Downloads
3246

Cite This Article

APA Style
Seki, M. , Seki, M. Lee, S. , Lee, S. Sakurada, K. , Sakurada, K. Miyawaki, Y. , Miyawaki, Y. Masuoka, A. , & Masuoka, A. (2023). Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia. Current Research in Public Health, 3(1), 5-11. https://doi.org/10.31586/gjmcr.2023.754
ACS Style
Seki, M. ; Seki, M. Lee, S. ; Lee, S. Sakurada, K. ; Sakurada, K. Miyawaki, Y. ; Miyawaki, Y. Masuoka, A. ; Masuoka, A. Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia. Current Research in Public Health 2023 3(1), 5-11. https://doi.org/10.31586/gjmcr.2023.754
Chicago/Turabian Style
Seki, Masafumi, Masafumi Seki. Seigi Lee, Seigi Lee. Kokyo Sakurada, Kokyo Sakurada. Yutaka Miyawaki, Yutaka Miyawaki. Ayumu Masuoka, and Ayumu Masuoka. 2023. "Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia". Current Research in Public Health 3, no. 1: 5-11. https://doi.org/10.31586/gjmcr.2023.754
AMA Style
Seki M, Seki MLee S, Lee SSakurada K, Sakurada KMiyawaki Y, Miyawaki YMasuoka A, Masuoka A. Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia. Current Research in Public Health. 2023; 3(1):5-11. https://doi.org/10.31586/gjmcr.2023.754 
@Article{crph754,
AUTHOR = {Seki, Masafumi and Lee, Seigi and Sakurada, Kokyo and Miyawaki, Yutaka and Masuoka, Ayumu and Kotajima, Futoshi},
TITLE = {Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2023},
NUMBER = {1},
PAGES = {5-11},
URL = {https://www.scipublications.com/journal/index.php/GJMCR/article/view/754},
ISSN = {2831-5162},
DOI = {10.31586/gjmcr.2023.754},
ABSTRACT = {Background: Pseudomonas aeruginosa (P. aeruginosa) is one of the most common pathogens in hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP). Recently, ceftolozane/tazobactam (CTLZ/TAZ) has been used to treat pneumonia due to P. aeruginosa. Case series: Two cases of P. aeruginosa pneumonia treated by CTLZ/TAZ that had been initially treated by piperacillin/tazobactam (PIPC/TAZ) are presented. (Case 1): A 76-year-old man who underwent esophagectomy developed severe pneumonia caused by P. aeruginosa infection and received oxygen by high-flow nasal canula. PIPC/TAZ was started, and he improved 10 days later. PIPC/TAZ was switched to sulbactam/ampicillin, but on day 14, his respiratory condition worsened, and septic shock developed. P. aeruginosa was isolated from his blood, and CTLZ/TAZ was started because the isolated P. aeruginosa showed resistance to PIPC/TAZ. Although he recovered on Day 28, and CTLZ/TAZ was switched to levofloxacin, his condition worsened again, and P. aeruginosa resistant to CTLZ/TAZ was isolated from his blood on day 32. Finally, he died of septicemia and renal failure. (Case 2) A 51-year-old woman who underwent surgery for a brain tumor developed VAP due to P. aeruginosa and was treated by PIPC/TAZ. Her pneumonia improved, but pneumothorax developed, and she was therefore switched to CTLZ/TAZ on day 7. Her pneumonia improved smoothly without bacteremia 10 days later. Conclusions: These data and cases suggest that CTLZ/TAZ was effective for severe P. aeruginosa pneumonia although the isolated P. aeruginosa was resistant to PIPC/TAZ. However, the duration of CTLZ/TAZ administration may need to be considered for pneumonia cases with bacteremia due to P. aeruginosa.},
}
%0 Journal Article
%A Seki, Masafumi
%A Lee, Seigi
%A Sakurada, Kokyo
%A Miyawaki, Yutaka
%A Masuoka, Ayumu
%A Kotajima, Futoshi
%D 2023
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 5-11

%T Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia
%M doi:10.31586/gjmcr.2023.754
%U https://www.scipublications.com/journal/index.php/GJMCR/article/view/754

TY  - JOUR
AU  - Seki, Masafumi
AU  - Lee, Seigi
AU  - Sakurada, Kokyo
AU  - Miyawaki, Yutaka
AU  - Masuoka, Ayumu
AU  - Kotajima, Futoshi
TI  - Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia
T2  - Current Research in Public Health
PY  - 2023
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 5
EP  - 11
UR  - https://www.scipublications.com/journal/index.php/GJMCR/article/view/754
AB  - Background: Pseudomonas aeruginosa (P. aeruginosa) is one of the most common pathogens in hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP). Recently, ceftolozane/tazobactam (CTLZ/TAZ) has been used to treat pneumonia due to P. aeruginosa. Case series: Two cases of P. aeruginosa pneumonia treated by CTLZ/TAZ that had been initially treated by piperacillin/tazobactam (PIPC/TAZ) are presented. (Case 1): A 76-year-old man who underwent esophagectomy developed severe pneumonia caused by P. aeruginosa infection and received oxygen by high-flow nasal canula. PIPC/TAZ was started, and he improved 10 days later. PIPC/TAZ was switched to sulbactam/ampicillin, but on day 14, his respiratory condition worsened, and septic shock developed. P. aeruginosa was isolated from his blood, and CTLZ/TAZ was started because the isolated P. aeruginosa showed resistance to PIPC/TAZ. Although he recovered on Day 28, and CTLZ/TAZ was switched to levofloxacin, his condition worsened again, and P. aeruginosa resistant to CTLZ/TAZ was isolated from his blood on day 32. Finally, he died of septicemia and renal failure. (Case 2) A 51-year-old woman who underwent surgery for a brain tumor developed VAP due to P. aeruginosa and was treated by PIPC/TAZ. Her pneumonia improved, but pneumothorax developed, and she was therefore switched to CTLZ/TAZ on day 7. Her pneumonia improved smoothly without bacteremia 10 days later. Conclusions: These data and cases suggest that CTLZ/TAZ was effective for severe P. aeruginosa pneumonia although the isolated P. aeruginosa was resistant to PIPC/TAZ. However, the duration of CTLZ/TAZ administration may need to be considered for pneumonia cases with bacteremia due to P. aeruginosa.
DO  - Treatment by Ceftolozane/Tazobactam for Pseudomonas Aeruginosa Pneumonia Patients with or without Bacteremia
TI  - 10.31586/gjmcr.2023.754
ER  -